108 related articles for article (PubMed ID: 10547193)
1. Fas ligand is frequently expressed in human pancreatic duct cell carcinoma.
Satoh K; Shimosegawa T; Masamune A; Hirota M; Koizumi M; Toyota T
Pancreas; 1999 Nov; 19(4):339-45. PubMed ID: 10547193
[TBL] [Abstract][Full Text] [Related]
2. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape.
Elnemr A; Ohta T; Yachie A; Kayahara M; Kitagawa H; Ninomiya I; Fushida S; Fujimura T; Nishimura G; Shimizu K; Miwa K
Int J Oncol; 2001 Jan; 18(1):33-9. PubMed ID: 11115536
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand.
von Bernstorff W; Spanjaard RA; Chan AK; Lockhart DC; Sadanaga N; Wood I; Peiper M; Goedegebuure PS; Eberlein TJ
Surgery; 1999 Jan; 125(1):73-84. PubMed ID: 9889801
[TBL] [Abstract][Full Text] [Related]
4. Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape.
Bernstorff WV; Glickman JN; Odze RD; Farraye FA; Joo HG; Goedegebuure PS; Eberlein TJ
Cancer; 2002 May; 94(10):2552-60. PubMed ID: 12173320
[TBL] [Abstract][Full Text] [Related]
5. Immunological escape mechanisms in pancreatic carcinoma.
Ungefroren H; Voss M; Bernstorff WV; Schmid A; Kremer B; Kalthoff H
Ann N Y Acad Sci; 1999 Jun; 880():243-51. PubMed ID: 10415870
[TBL] [Abstract][Full Text] [Related]
6. Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells.
Lee TB; Min YD; Lim SC; Kim KJ; Jeon HJ; Choi SM; Choi CH
J Gastroenterol Hepatol; 2002 Jan; 17(1):32-8. PubMed ID: 11895550
[TBL] [Abstract][Full Text] [Related]
7. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer.
Müllauer L; Mosberger I; Grusch M; Rudas M; Chott A
J Pathol; 2000 Jan; 190(1):20-30. PubMed ID: 10640988
[TBL] [Abstract][Full Text] [Related]
8. The Fas/Fas-ligand system: a mechanism for immune evasion in human breast carcinomas.
Gutierrez LS; Eliza M; Niven-Fairchild T; Naftolin F; Mor G
Breast Cancer Res Treat; 1999 Apr; 54(3):245-53. PubMed ID: 10445423
[TBL] [Abstract][Full Text] [Related]
9. CD97, CD95 and Fas-L clearly discriminate between chronic pancreatitis and pancreatic ductal adenocarcinoma in perioperative evaluation of cryocut sections.
Boltze C; Schneider-Stock R; Aust G; Mawrin C; Dralle H; Roessner A; Hoang-Vu C
Pathol Int; 2002 Feb; 52(2):83-8. PubMed ID: 11940212
[TBL] [Abstract][Full Text] [Related]
10. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.
Ungefroren H; Voss M; Jansen M; Roeder C; Henne-Bruns D; Kremer B; Kalthoff H
Cancer Res; 1998 Apr; 58(8):1741-9. PubMed ID: 9563493
[TBL] [Abstract][Full Text] [Related]
11. Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma.
Tsuji S; Hosotani R; Yonehara S; Masui T; Tulachan SS; Nakajima S; Kobayashi H; Koizumi M; Toyoda E; Ito D; Kami K; Mori T; Fujimoto K; Doi R; Imamura M
Int J Cancer; 2003 Aug; 106(1):17-25. PubMed ID: 12794752
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system.
Zhu Q; Liu JY; Xu HW; Yang CM; Zhang AZ; Cui Y; Wang HB
World J Gastroenterol; 2005 Oct; 11(39):6125-9. PubMed ID: 16273638
[TBL] [Abstract][Full Text] [Related]
13. Expression of Fas and anti-Fas-mediated apoptosis in human hepatocellular carcinoma cell lines.
Yano H; Fukuda K; Haramaki M; Momosaki S; Ogasawara S; Higaki K; Kojiro M
J Hepatol; 1996 Oct; 25(4):454-64. PubMed ID: 8912144
[TBL] [Abstract][Full Text] [Related]
14. Okadaic acid stimulates apoptosis through expression of Fas receptor and Fas ligand in human oral squamous carcinoma cells.
Goto K; Fukuda J; Haneji T
Oral Oncol; 2002 Jan; 38(1):16-22. PubMed ID: 11755816
[TBL] [Abstract][Full Text] [Related]
15. Co-expression of Fas (APO-1, CD95)/Fas ligand by BeWo and NJG choriocarcinoma cell lines.
Rajashekhar G; Loganath A; Roy AC; Mongelli JM
Gynecol Oncol; 2003 Oct; 91(1):101-11. PubMed ID: 14529668
[TBL] [Abstract][Full Text] [Related]
16. Fas and Fas-ligand expression in human pancreatic cancer.
Kornmann M; Ishiwata T; Kleeff J; Beger HG; Korc M
Ann Surg; 2000 Mar; 231(3):368-79. PubMed ID: 10714630
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of Fas-ligand by neuroblastoma: a novel mechanism of tumor-cell killing.
Takamizawa S; Okamoto S; Wen J; Bishop W; Kimura K; Sandler A
J Pediatr Surg; 2000 Feb; 35(2):375-9. PubMed ID: 10693700
[TBL] [Abstract][Full Text] [Related]
18. Oral cancer cell lines can use multiple ligands, including Fas-L, TRAIL and TNF-alpha, to induce apoptosis in Jurkat T cells: possible mechanisms for immune escape by head and neck cancers.
Kassouf N; Thornhill MH
Oral Oncol; 2008 Jul; 44(7):672-82. PubMed ID: 17996489
[TBL] [Abstract][Full Text] [Related]
19. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.
Gastman BR; Atarshi Y; Reichert TE; Saito T; Balkir L; Rabinowich H; Whiteside TL
Cancer Res; 1999 Oct; 59(20):5356-64. PubMed ID: 10537320
[TBL] [Abstract][Full Text] [Related]
20. Fas-Fas ligand system mediates luteal cell death in bovine corpus luteum.
Taniguchi H; Yokomizo Y; Okuda K
Biol Reprod; 2002 Mar; 66(3):754-9. PubMed ID: 11870083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
